|
1
|
Kelly BD, Miller N, Sweeney KJ, Durkan GC,
Rogers E, Walsh K and Kerin MJ: A circulating MicroRNA signature as
a biomarker for prostate cancer in a high risk group. J Clin Med.
4:1369–1379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
3
|
Salinas CA, Tsodikov A, Ishak-Howard M and
Cooney KA: Prostate cancer in young men: An important clinical
entity. Nat Rev Urol. 11:317–323. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rebello RJ, Oing C, Knudsen KE, Loeb S,
Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG:
Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Kratzer TB, Wagle NS, Sung H
and Jemal A: Cancer statistics, 2026. CA Cancer J Clin.
76:e700432026.PubMed/NCBI
|
|
6
|
Pron G: Prostate-specific antigen
(PSA)-based population screening for prostate cancer: An
evidence-based analysis. Ont Health Technol Assess Ser. 15:1–64.
2015.
|
|
7
|
Kang BJ, Jeun M, Jang GH, Song SH, Jeong
IG, Kim CS, Searson PC and Lee KH: Diagnosis of prostate cancer via
nanotechnological approach. Int J Nanomedicine. 10:6555–6569.
2015.PubMed/NCBI
|
|
8
|
Cuzick J, Thorat MA, Andriole G, Brawley
OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et
al: Prevention and early detection of prostate cancer. Lancet
Oncol. 15:e484–e492. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hyldgård VB, Laursen KR, Poulsen J and
Søgaard R: Robot-assisted surgery in a broader healthcare
perspective: A difference-in-difference-based cost analysis of a
national prostatectomy cohort. BMJ Open. 7:e0155802017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hohwü L, Borre M, Ehlers L and Venborg
Pedersen K: A short-term cost-effectiveness study comparing
robot-assisted laparoscopic and open retropubic radical
prostatectomy. J Med Econ. 14:403–409. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Burkhard P, Stetefeld J and Strelkov SV:
Coiled coils: A highly versatile protein folding motif. Trends Cell
Biol. 11:82–88. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anazi S, Maddirevula S, Faqeih E,
Alsedairy H, Alzahrani F, Shamseldin HE, Patel N, Hashem M, Ibrahim
N, Abdulwahab F, et al: Clinical genomics expands the morbid genome
of intellectual disability and offers a high diagnostic yield. Mol
Psychiatry. 22:615–624. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meier N, Bruder E, Lapaire O, Hoesli I,
Kang A, Hench J, Hoeller S, De Geyter J, Miny P, Heinimann K, et
al: Exome sequencing of fetal anomaly syndromes: Novel
phenotype-genotype discoveries. Eur J Hum Genet. 27:730–737. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan C, Meng L, Lv M, He X, Sha Y, Tang D,
Tan Y, Hu T, He W, Tu C, et al: Bi-allelic variants in DNHD1 cause
flagellar axoneme defects and asthenoteratozoospermia in humans and
mice. Am J Hum Genet. 109:157–171. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martinez G, Barbotin AL, Cazin C, Wehbe Z,
Boursier A, Amiri-Yekta A, Daneshipour A, Hosseini SH, Rives N,
Feraille A, et al: New mutations in DNHD1 cause multiple
morphological abnormalities of the sperm flagella. Int J Mol Sci.
24:25592023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu S, Hivert MF, Cardenas A, Zhong J,
Rifas-Shiman SL, Agha G, Colicino E, Just AC, Amarasiriwardena C,
Lin X, et al: Exposure to low levels of lead in utero and umbilical
cord blood DNA methylation in project viva: An epigenome-wide
association study. Environ Health Perspect. 125:0870192017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schiavo G, Greensmith L, Hafezparast M and
Fisher EMC: Cytoplasmic dynein heavy chain: The servant of many
masters. Trends Neurosci. 36:641–651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ung C, Sanchez AV, Shen L, Davoudi S,
Ahmadi T, Navarro-Gomez D, Chen CJ, Hancock H, Penman A, Hoadley S,
et al: Whole exome sequencing identification of novel candidate
genes in patients with proliferative diabetic retinopathy. Vision
Res. 139:168–176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jones AC, Patki A, Claas SA, Tiwari HK,
Chaudhary NS, Absher DM, Lange LA, Lange EM, Zhao W, Ratliff SM, et
al: Differentially methylated DNA regions and left ventricular
hypertrophy in african americans: A HyperGEN study. Genes (Basel).
13:17002022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu S, Wei W, Wang P, Liu C, Jiang X, Li
T, Li F, Wu Y, Chen S, Sun K and Xu R: LOF variants identifying
candidate genes of laterality defects patients with congenital
heart disease. PLoS Genet. 18:e10105302022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu MD, Liu SL, Feng YZ, Liu Q, Shen M, Zhi
Q, Liu Z, Gu DM, Yu J, Shou LM, et al: Genomic characteristics of
pancreatic squamous cell carcinoma, an investigation by using high
throughput sequencing after in-solution hybrid capture. Oncotarget.
8:14620–14635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin Z, Xu H, Yang R, Li Z, Zheng H, Zhang
Z, Peng J, Zhang X, Qi S, Liu Y and Huang G: Effective treatment of
a BRAF V600E-mutant epithelioid glioblastoma patient by
vemurafenib: A case report. Anticancer Drugs. 33:100–104. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang L, Zou T, Liang W, Mo C, Wei J, Deng
Y and Ou M: High-throughput sequencing reveals that rotundine
inhibits colorectal cancer by regulating prognosis-related genes. J
Pers Med. 13:5502023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li ZT, Zhu H, Wang XJ, Zhang LH and Zhang
L: Histone deacetylase 6: A potential therapeutic target for drug
development. Bioorg Chem. 165:1089322025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang Y, Wang Y, Xing J, Li J and Zhang K:
The regulatory mechanisms and treatment of HDAC6 in immune
dysregulation diseases. Front Immunol. 16:16535882025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ran J, Yang Y, Li D, Liu M and Zhou J:
Deacetylation of α-tubulin and cortactin is required for HDAC6 to
trigger ciliary disassembly. Sci Rep. 5:129172015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou M, Zheng H, Li Y, Huang H, Min X, Dai
S, Zhou W, Chen Z, Xu G and Chen Y: Discovery of a novel AR/HDAC6
dual inhibitor for prostate cancer treatment. Aging (Albany NY).
13:6982–6998. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gibbs A, Schwartzman J, Deng V and Alumkal
J: Sulforaphane destabilizes the androgen receptor in prostate
cancer cells by inactivating histone deacetylase 6. Proc Natl Acad
Sci USA. 106:16663–16668. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson
JB and Wang Z: HDAC6 regulates androgen receptor hypersensitivity
and nuclear localization via modulating Hsp90 acetylation in
castration-resistant prostate cancer. Mol Endocrinol. 23:1963–1972.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peng J, Xie F, Qin P, Liu Y, Niu H, Sun J,
Xue H, Zhao Q, Liu J and Wu J: Recent development of selective
inhibitors targeting the HDAC6 as anti-cancer drugs: Structure,
function and design. Bioorg Chem. 138:1066222023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pulya S, Amin SA, Adhikari N, Biswas S,
Jha T and Ghosh B: HDAC6 as privileged target in drug discovery: A
perspective. Pharmacol Res. 163:1052742021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu SW, Wu CC, Dong SW, Tzou KY, Chen CH,
Wang YH, Liu YN, Liao CC and Li CH: Implications of the KHDC4-TRAF2
axis in the context of prostate cancer prognosis. Aging (Albany
NY). 17:1544–1570. 2025.PubMed/NCBI
|
|
33
|
Wu CC, Hu SW, Dong SW, Tzou KY and Li CH:
The prognostic and neuroendocrine implications of SLC25A29-mediated
biomass signature in prostate cancer. Geroscience. 47:4711–4732.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li CH, Chan MH and Chang YC: The role of
fructose 1,6-bisphosphate-mediated glycolysis/gluconeogenesis genes
in cancer prognosis. Aging (Albany NY). 14:3233–3258. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li CH, Chan MH, Chang YC and Hsiao M: The
CHST11 gene is linked to lung cancer and pulmonary fibrosis. J Gene
Med. 24:e34512022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li CH, Fang CY, Chan MH, Chen CL, Chang YC
and Hsiao M: The cytoplasmic expression of FSTL3 correlates with
colorectal cancer progression, metastasis status and prognosis. J
Cell Mol Med. 27:672–686. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li CH, Fang CY, Chan MH, Lu PJ, Ger LP,
Chu JS, Chang YC, Chen CL and Hsiao M: The activation of EP300 by
F11R leads to EMT and acts as a prognostic factor in
triple-negative breast cancers. J Pathol Clin Res. 9:165–181. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim S, Lee K, Choi JH, Ringstad N and
Dynlacht BD: Nek2 activation of Kif24 ensures cilium disassembly
during the cell cycle. Nat Commun. 6:80872015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Valenzuela-Fernández A, Cabrero JR,
Serrador JM and Sánchez-Madrid F: HDAC6: A key regulator of
cytoskeleton, cell migration and cell-cell interactions. Trends
Cell Biol. 18:291–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen P and Zhang YL: Role of HDAC6 in
carcinomas. Discov Oncol. 17:2402026. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Godbole AM and Njar VCO: New insights into
the androgen-targeted therapies and epigenetic therapies in
prostate cancer. Prostate Cancer. 2011:9187072011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ye PC, Leu WJ, Yeh TY, Hsu YT, Lin YC, Wei
ZY, Chen YC, Chiang YC, Hsu JL, Chan SH, et al: A novel HDAC6
inhibitor interferes microtubule dynamics and spindle assembly
checkpoint and sensitizes cisplatin-induced apoptosis in
castration-resistant prostate cancer. Prostate. 84:605–619. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pramanik SD, Kumar Halder A, Mukherjee U,
Kumar D, Dey YN and R M: Potential of histone deacetylase
inhibitors in the control and regulation of prostate, breast and
ovarian cancer. Front Chem. 10:9482172022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Eguether T and Hahne M: Mixed signals from
the cell's antennae: Primary cilia in cancer. EMBO Rep.
19:e465892018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mill P, Christensen ST and Pedersen LB:
Primary cilia as dynamic and diverse signalling hubs in development
and disease. Nat Rev Genet. 24:421–441. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kiseleva AA, Nikonova AS and Golemis EA:
Patterns of ciliation and ciliary signaling in cancer. Rev Physiol
Biochem Pharmacol. 185:87–105. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng M, Zhou J and Wang Y: Primary cilia
in cancer: Structures, functions, mechanisms, and therapeutic
implications. Cancer Biol Med. 22:1455–1472. 2025.PubMed/NCBI
|
|
49
|
Collinson R and Tanos B: Primary cilia and
cancer: A tale of many faces. Oncogene. 44:1551–1566. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kaushal JB, Seshacharyulu P, Batra SK and
Muniyan S: Multifaceted role of primary cilia and ciliary proteins:
A potential nexus for hedgehog signaling and prostate cancer.
Biochim Biophys Acta Mol Basis Dis. 1872:1681202026. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
O'Toole SM and Chapple JP: Primary cilia:
A link between hormone signalling and endocrine-related cancers?
Biochem Soc Trans. 44:1227–1234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Matissek SJ and Elsawa SF: GLI3: A
mediator of genetic diseases, development and cancer. Cell Commun
Signal. 18:542020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gao L and Alumkal J: Epigenetic regulation
of androgen receptor signaling in prostate cancer. Epigenetics.
5:100–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tran HY, Lin CL, Lin HY, Shen CJ, Sharma
R, Liou JP and Hsu TI: A dual CYP17A1/HDAC6 inhibitor for targeted
prostate cancer therapy. FASEB J. 39:e711522025. View Article : Google Scholar : PubMed/NCBI
|
